This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| INSR | |
|---|---|
| Name | Insulin receptor |
| Hgnc id | 6088 |
| Entrezgene | 3643 |
| Omim | 147670 |
| Uniprot | P06213 |
| Chromosomal location | 19p13.2 |
INSR INSR encodes a transmembrane tyrosine kinase receptor that mediates cellular responses to insulin and plays central roles in metabolic homeostasis. The receptor is expressed broadly across Homo sapiens tissues and is implicated in physiological processes studied by researchers at institutions such as National Institutes of Health, Harvard Medical School, and Massachusetts Institute of Technology. Mutations and dysregulation of the receptor are linked to clinical syndromes characterized in literature from groups including Mayo Clinic, Johns Hopkins Hospital, and Cleveland Clinic.
INSR produces a heterotetrameric receptor composed of two extracellular alpha subunits and two transmembrane beta subunits; this topology was elucidated in classic studies at Cold Spring Harbor Laboratory and Max Planck Society laboratories. The receptor binds insulin studied by investigators at Eli Lilly and Company, Novo Nordisk, and academic teams at University of Cambridge. Seminal biochemical characterization involved techniques developed at Salk Institute and Rockefeller University.
The gene maps to chromosome 19p13.2 and spans multiple exons identified in genome projects coordinated by Human Genome Project consortia and analyzed by groups at Wellcome Trust Sanger Institute. Alternative splicing produces isoforms with differing exon composition, a phenomenon examined by researchers at Stanford University and University of Oxford. The protein contains an extracellular ligand-binding domain, a transmembrane helix, and an intracellular tyrosine kinase domain homologous to receptors such as the Epidermal growth factor receptor and Platelet-derived growth factor receptor. Structural insights derived from crystallographic studies at European Molecular Biology Laboratory and cryo-EM work at University of California, San Francisco clarified the conformation changes upon ligand engagement.
Upon insulin binding, the receptor undergoes autophosphorylation of key tyrosine residues within the kinase domain, a mechanism first described in classical papers from University of Pennsylvania and Yale University. Activated receptor phosphorylates substrates including members of the IRS (insulin receptor substrate) family and adaptor proteins studied in laboratories at University of Toronto and Imperial College London. Downstream effects regulate glucose uptake via translocation of transporters like GLUT4 characterized in experiments at University of California, Berkeley and Weizmann Institute of Science. The receptor also modulates lipid metabolism, protein synthesis, and cell growth pathways relevant to research at Fred Hutchinson Cancer Research Center and Dana-Farber Cancer Institute.
Pathogenic variants produce syndromes ranging from severe insulin resistance to contrastive metabolic phenotypes documented in clinical series at Boston Children's Hospital and Mount Sinai Hospital. Associations with type 2 diabetes mellitus have been reported in population studies by Framingham Heart Study investigators and genome-wide analyses from International HapMap Project collaborators. Monogenic insulin resistance and conditions such as leprechaunism were described in case reports from Mayo Clinic clinicians and geneticists at University of Pittsburgh Medical Center. Altered receptor signaling contributes to oncogenic processes highlighted in cancer research at Memorial Sloan Kettering Cancer Center and National Cancer Institute.
Receptor activity is regulated by endocytosis pathways characterized by work at European Bioinformatics Institute and post-translational modifications such as ubiquitination studied by teams at Cold Spring Harbor Laboratory and Harvard Medical School. Cross-talk occurs with signaling cascades including the PI3K–AKT pathway and the MAPK pathway, which have been major focus areas at Broad Institute and Johns Hopkins University. Feedback mechanisms involve phosphatases like PTEN and kinases such as mTOR, subjects of research at Salk Institute and University of Cambridge.
Therapeutic modulation includes development of insulin analogues by pharmaceutical companies such as Novo Nordisk and Sanofi, and small-molecule modulators investigated at Pfizer and GlaxoSmithKline. Preclinical and clinical studies exploring receptor agonists, sensitizers, and gene therapies have been conducted at centers including National Institutes of Health and Stanford University School of Medicine. Biomarker and precision-medicine approaches leveraging data from UK Biobank and 1000 Genomes Project aim to stratify risk and guide interventions. Ongoing basic research employs model organisms like Mus musculus and Drosophila melanogaster to dissect conserved receptor functions, with resources from Jackson Laboratory and Bloomington Drosophila Stock Center.
Category:Human proteins Category:Receptor tyrosine kinases